G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity ...

Just as we receive news of the demise of our good old faithful T-Mobile G1, I also have news of some testing I’ve been doing while I had the Samsung Vibrant here. The tests are all run on the T-Mobile ...

G1 Therapeutics’ cancer drug trilaciclib has failed to beat placebo against multiple efficacy measures in phase 2. Trilaciclib performed well against its neutropenia-related primary endpoints but fell ...